This post-hoc subgroup analysis demonstrates that ramucirumab is likely to be beneficial in Asian patients with advanced HCC and elevated AFP level who are intolerant to, or have progressed on, sorafenib. This evidence concerns the gene AFP and hepatocellular carcinoma.